摘要
目的观察紫杉醇脂质体单药一线治疗老年晚期非小细胞肺癌(NSCLC)的近期疗效及不良反应。方法 21例经病理或细胞学确诊初治老年非小细胞肺癌患者,年龄≥65岁,KPS评分≥70分,其中19例合并程度不等的各种疾病。采用紫杉醇脂质体175mg/m2,静脉给药,每3周给药1次。2周期后评价疗效,观察近期疗效和化疗期间不良反应。结果完全缓解(CR)0例,部分缓解(PR)5例(23.8%),稳定(SD)10例(47.6%),进展(PD)6例(28.6%),有效率RR23.8%,疾病控制率DCR为71.4%。主要不良反应为血液学毒性、胃肠道反应、肝功能损害,但均以Ⅰ、Ⅱ级为主。发生Ⅲ～Ⅳ级粒细胞减少为3例(14.2%),无感染与发热。无因化疗不良反应导致延迟或终止治疗,无化疗相关性死亡。结论一般状况较好的老年晚期NSCLC患者采用紫杉醇脂质体单药化疗安全、有效,不良反应低,患者耐受性好。
Objective To observe efficacy and side effects of Paclitaxel liposome single-agent on the first-line treatment of elderly patients with advanced non-small cell lung cancer （NSCLC）.Methods Twenty one elderly patients （age≥65 years,KPS≥70） with histologically or cytologically diagnosed advanced NSCLC were treated with Paclitaxel liposome （at a dose of 175mg/m2 day1 as a 3-h infusion on day 1,21days as one cycle）.The therapeutic efficacy was evaluated after 2 cycles of the chemotherapy.Results Among 21 patients all were evaluated for response and toxicity.The overall response rate was 23.8% with complete and partial response rate of 0.0% and 23.8%,respectively; the disease control rate was 71.4%.Adverse events were generally mild,mostly including myelo suppression,gastrointestinal and liver function impairment.There was no treatment-related death.Conclusion The treatment of Paclitaxel liposome showed an effective antitumor activity and a favorable toxicity profile in elderly patientswith NSCLC.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2010年第12期1423-1425,共3页
Cancer Research on Prevention and Treatment
关键词
非小细胞肺癌
老年
紫杉醇脂质体
化疗
Non-small cell lung cancer（NSCLC）
Elderly
Paclitaxel liposome
Chemotherapy
